瑞格列奈治疗肥胖与非肥胖2型糖尿病的Meta分析

摘要

目的:探讨比较瑞格列奈治疗肥胖与非肥胖2型糖尿病(T2DM)的疗效和安全性.方法:计算机检索PubMed、EMbase、Cochrane图书馆、万方、维普、CNKI,查找瑞格列奈治疗肥胖与非肥胖T2DM的研究,由2名研究人员严格按照纳入与排除标准对文献进行筛选、数据提取和质量评价后,采用RevMan 5.2软件进行Meta分析.结果:共纳入6项临床对照试验(CCT),789例患者.Meta分析结果显示:在降低糖化血红蛋白[MD=–0.35,95%CI(–0.54,–0.15),P=0.0005]和体重指数[MD=–3.33,95%CI(–4.12,–2.54),P0.10),I2=0%)]、FPG[P=0.01(P0.10),I2=0%]、ADR[P=0.44(P>0.10),I2=0%].结论:瑞格列奈治疗肥胖型2型糖尿病患者的疗效优于非肥胖型,且其不良反应发生率更低.%Objective: To evaluate the efifcacy and safety of repaglinide in the treatment of obese and non-obese patients with type 2 diabetes (T2DM).Methods: Databases from PubMed, EMbase, The Cochrane Library, Wanfang, VIP and CNKI were searched to extract the studies about repaglinide in the treatment of obese and non-obese patients with T2DM. After the screening, according to the inclusion and exclusion criteria, the data extracting and quality evaluating were performed by 2 researchers, and then meta-analysis was performed using RevMan 5.2 software.Results:A total of 6 controlled clinical trials (CCT) including 789 patients involved in the study. The results of meta-analysis showed that the effects of repaglinide in lowering HbAlc [MD = – 0.35, 95%CI(– 0.54, – 0.15),P = 0.0005] and BMI [MD = – 3.33, 95%CI(– 4.12, – 2.54),P 0.10),I2 = 0%)], FPG [P = 0.01 (P 0.10),I2 = 0%] and ADR [P = 0.44 (P > 0.10),I2 = 0%].Conclusion: The effect of repaglinide in the treatment of obese patients with T2DM was more effective than that in non-obese patients with T2DM, while the risk of ADR was lower.